TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01694706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir
Description: medium dose of faldaprevir
Study: NCT03103438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089
Study: NCT01342471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV commercial stepping
Description: Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30-min walk
Description: Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention
Study: NCT00349973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
Study: NCT02471729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnligHTN™ Renal Denervation System
Description: The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
Study: NCT03849924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Self-affirmation implementation intentions in the form of a questionnaire.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Self-affirmation implementation intentions in the form of a questionnaire.
Study: NCT02923232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accommodative contact lens
Description: Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
Study: NCT00347646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: 27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
Study: NCT01694706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: medium dose of omeprazole
Study: NCT04075656

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UrApp
Description: Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
Study: NCT04422210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
Study: NCT03599427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic lidocaine
Description: Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
Study: NCT04734353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 5mg
Description: Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60mg
Description: Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
Study: NCT04422210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
Study: NCT05958992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: Participants will self-administer experimenter-provided e-cigarettes
Study: NCT04422210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.
Study: NCT01827176

Intervention type: OTHER
Intervention: Recurrent Acute Rhinosinusitis
Description: Clinical Characteristic of Recurrent Acute Rhinosinusitis
Study: NCT00574106

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength)
Study: NCT03981120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser and Traditional Acupuncture
Description: Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
Study: NCT02623101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy
Description: Non-invasive imaging of the lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch biopsy
Description: Obtaining a skin sample of the suspicious lesion under local anesthetics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision
Description: Excision of the basal cell carcinoma lesion under local anesthetics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical excision
Description: Excision of the basal cell carcinoma lesion under local anesthetics
Study: NCT03045549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital biofeedback system
Description: The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional home-based rehabilitation
Description: Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application
Study: NCT04237987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin and corticosteroid
Description: ciclosporin and corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclosporin and corticosteroid
Description: ciclosporin and corticosteroid
Study: NCT04018534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Verbal/Written Education
Description: This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Assisted Education
Description: The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hands-on Training
Description: The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
Study: NCT03652792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan (Zhaoke)
Description: Azilsartan 20mg tablets from Zhaoke

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan (Zhaoke)
Description: Azilsartan 20mg tablets from Zhaoke

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan (Takeda)
Description: Azilva 20mg tablets from Takeda

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan (Takeda)
Description: Azilva 20mg tablets from Takeda
Study: NCT03292757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Fluorescent dye - indocyanine green

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Fluorescent dye - indocyanine green
Study: NCT03475641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral nerve blockade
Description: The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The current standard treatment
Description: Tumescent anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The current standard treatment
Description: Tumescent anesthesia.
Study: NCT02464501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paclitaxel administration using the OPC
Study: NCT01384344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observational
Description: Observation during a physical exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observational
Description: Observation during a physical exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observational
Description: Observation during a physical exercise
Study: NCT00665119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: 0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: NaCl 0.9 %
Study: NCT00857194

Intervention type: PROCEDURE
Intervention: 2 hour Oral Glucose Tolerance Test
Description: Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.

Intervention type: PROCEDURE
Intervention: Fat Meal Test
Description: A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
Study: NCT02376452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 2mg/m2 iv gtt, d1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 iv gtt, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 iv gtt, d1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-FU 400mg/m2 iv, 2400mg/m2 civ 46h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: 400mg/m2 iv gtt,d1
Study: NCT04419636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: capsules, orally
Study: NCT01319734

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C supplementation 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: this group receiving glyburide 5 mg alone
Study: NCT04965779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Binder
Description: Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postpartum nursing care
Description: Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum nursing care
Description: Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
Study: NCT02914964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swank Diet
Description: A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wahls Elimination Diet
Description: A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
Study: NCT00934999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burch urethropexy
Description: Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
Study: NCT02980029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo